Advances in the management of gout and hyperuricaemia

References

• Mikuls T. R., MacLean C. H., Olivieri J., Patino F., Allison J. J., Farrar J. T., et al. Quality of care indicators for gout management. Arthritis Rheum 2004; 50: 937–43
   PubMed Web of Science ®Google Scholar
• Schumacher H. R., Jr., Edwards L. N., Perez‐Ruiz F., Becker M., Chen L. X., Furst D. E., et al. Outcome measures for acute and chronic gout. J Rheumatol 2005; 32: 2452–5
   PubMed Web of Science ®Google Scholar
• Wortmann R. L. Gout and hyperuricemia. Curr Opin Rheumatol 2002; 14: 281–6
   PubMed Web of Science ®Google Scholar
• Schlesinger N., Detry M. A., Holland B. K., Baker D. G., Beutler A. M., Rull M., et al. Local ice therapy during bouts of acute gouty arthritis. J Rheumatol 2002; 29: 331–6
   PubMed Web of Science ®Google Scholar
• Wortmann R. L. Treatment of acute gouty arthritis: one physician's approach and where this management stands relative to developments in the field. Curr Rheumatol Rep 2004; 6: 235–9
   PubMedGoogle Scholar
• Emmerson B. T. The management of gout. N Engl J Med 1996; 334: 445–51
   PubMed Web of Science ®Google Scholar
• Fam A. G. ‘Problem’ gout: clinical challenges, effective solutions. J Musculoskelet Med 1997; 14: 63–77
   Google Scholar
• Schumacher H. R Jr., Boice J. A., Daikh D. I., Mukhopadhyay S., Malmstrom K., Ng J., et al. Randomized double blind trial of etoricoxib and indomethacin in treatment of acute gouty arthritis. Br Med J 2002; 324: 1488–92
   PubMed Web of Science ®Google Scholar
• Dieppe P. A. Investigation and management of gout in the young and the elderly. Ann Rheum Dis 1991; 50: 263–66
   PubMed Web of Science ®Google Scholar
• Fendrick A. M., Garabedian‐Ruffalo S. M. A clinician's guide to the selection of NSAID therapy. Pharm Ther 2002; 27: 579–82
   Google Scholar
• Molad Y. Update on colchicines and its mechanism of action. Curr Rheumatol Rep 2002; 4: 252–6
   PubMedGoogle Scholar
• Kim K. Y., Ralph Schumacher H., Hunsche E., Wertheimer A. I., Kong S. X. A literature review of the epidemiology and treatment of acute gout. Clin Ther 2003; 25: 1593–617
   PubMed Web of Science ®Google Scholar
• Ahern M. J., Reid C., Gordon T. P., McCredie M., Brooks P. M., Jones M. Does colchicine work? The results of the first controlled study in acute gout. Aust N Z J Med 1987; 17: 301–4
   PubMedGoogle Scholar
• Iacobuzio‐Donahue C. A., Lee E. L., Abraham S. C., Yardley J. H., Wu T. T. Colchicine toxicity. Distinct morphologic findings in gastrointestinal biopsies. Am J Surg Path 2001; 25: 1067–70
   PubMed Web of Science ®Google Scholar
• Wallace S. L., Singer J. Z. Review: systemic toxicity associated with the intravenous administration of colchicine – guidelines for use. J Rheumatol 1988; 15: 495–500
   PubMed Web of Science ®Google Scholar
• Baethge B. A., Work J., Landreneau M. D., McDonald J. C. Tophaceous gout in patients with renal transplants treated with cyclosporine A. J Rheumatol 1993; 20: 718–20
   PubMed Web of Science ®Google Scholar
• Gerster J. C., Landry M., Dufresne L., Meuwly J. Y. Imaging of tophaceous gout: computed tomography provides specific images compared to magnetic resonance imaging and ultrasonography. Ann Rheum Dis 2002; 61: 52–4
   PubMed Web of Science ®Google Scholar
• Chattopadhyay I., Shetty H. G., Routledge P. A., Jeffery J. Colchicine induced rhabdomyolysis. Postgrad Med J 2001; 77: 191–4
   PubMed Web of Science ®Google Scholar
• Ferraz M. B., O'Brien B. A cost effectiveness analysis of urate lowering drugs in nontophaceous recurrent gouty arthritis. J Rheumatol 1995; 22: 908–13
   PubMed Web of Science ®Google Scholar
• Evans T. I., Wheeler M. T., Small R. E., Breitbach S. A., Sanders K. M., Roberts W. N. A comprehensive investigation of inpatient intravenous colchicines use shows more education is needed. J Rheumatol 1996; 23: 143–8
   PubMed Web of Science ®Google Scholar
• Rosenthal A. K., Ryan L. M. Treatment of refractory crystal‐associated arthritis. Rheum Dis Clin North Am 1995; 21: 151–61
   PubMed Web of Science ®Google Scholar
• Alloway J. A., Moriarty M. J., Hoogland Y. T., Nashold D. J. Comparison of triamcinolone acetonide with indomethacin in the treatment of acute gouty arthritis. J Rheumatol 1993; 20: 111–13
   PubMed Web of Science ®Google Scholar
• Axelrod D., Preston S. Comparison of parenteral adrenocorticotropic hormone with oral indomethacin in the treatment of acute gout. Arthritis Rheum 1988; 33: 803–5
   Web of Science ®Google Scholar
• Clive D. M. Renal transplant‐associated hyperuricemia and gout. J Am Soc Nephrol 2000; 11: 974–9
   PubMed Web of Science ®Google Scholar
• Terkeltaub R. A. Gout. N Engl J Med 2003; 349: 1647–55
   PubMed Web of Science ®Google Scholar
• Groff G. D., Franck W. A., Raddatz D. A. Systemic steroid therapy for acute gout: a clinical trial and review of the literature. Semin Arthritis Rheum 1990; 19: 329–36
   PubMed Web of Science ®Google Scholar
• Fam A. G. Current therapy of acute microcrystalline arthritis and the role of corticosteroids. J Clin Rheumatol 1997; 3: 35–40
   PubMedGoogle Scholar
• Siegel L. B., Alloway J. A., Nashel D. J. Comparison of adrenocorticotropic hormone and triamcinolone acetonide in the treatment of acute gouty arthritis. J Rheumatol 1994; 21: 1325–7
   PubMed Web of Science ®Google Scholar
• Schlesinger N., Schumacher H. R Jr. Gout: can management be improved?. Curr Opin Rheumatol 2001; 13: 240–4
   PubMed Web of Science ®Google Scholar
• Schlesinger N., Baker D. G., Schumacher H. R Jr. How well have diagnostic tests and therapies for gout been evaluated?. Curr Opin Rheumatol 1999; 11: 441–5
   PubMedGoogle Scholar
• Getting S. J., Christian H. C., Flower R. J., Perretti M. Activation of melanocortin type 3 receptor as a molecular mechanism for adrenocorticotropic hormone efficacy in gouty arthritis. Arthritis Rheum 2002; 46: 2765–75
   PubMed Web of Science ®Google Scholar
• Ritter 1., Kerr L. D., Valeriano‐Marcet J., Spirea H. ACTH revisited: effective treatment for acute crystal induced synovitis in patients with multiple medical problems. J Rheumatol 1994; 21: 696–9
   PubMed Web of Science ®Google Scholar
• McGill N. W. Gout and other crystal‐associated arthropathies. Bailliere's Best Pract Res Clin Rheumatol 2000; 14: 445–60
   PubMed Web of Science ®Google Scholar
• Bull P. W., Scott J. T. Intermittent control of hyperuricemia in the treatment of gout. J Rheumatol 1989; 16: 1246–8
   PubMed Web of Science ®Google Scholar
• Van Lieshout‐Zuidema M. F., Breedveld F. C. Withdrawal of long‐term antihyperuricemic therapy in tophaceous gout. J Rheumatol 1993; 20: 1383–5
   PubMed Web of Science ®Google Scholar
• Nakayama D. A., Barthelemy C., Carrera G., Lightfoot R. W., Jr., Wortmann R. L. Tophaceous gout: a clinical and radiographic assessment. Arthritis Rheum 1984; 27: 468–73
   PubMed Web of Science ®Google Scholar
• Li‐Yu J., Clayburne G., Sieck M., Beutler A., Rull M., Eisner E., et al. Treatment of chronic gout. Can we determine when urate stores are depleted enough to prevent attacks of gout?. J Rheumatol 2001; 28: 577–80
   PubMed Web of Science ®Google Scholar
• Chen L. X., Schumacher H. R. Diagnosis and management of gout. J Sci Commun 2003; 10: 337–42
   Google Scholar
• Shoji A., Yamanaka H., Kamatani N. A retrospective study of the relationship between serum urate level and recurrent attacks of gouty arthritis: evidence for reduction of recurrent gouty arthritis with antihyperuricemic therapy. Arthritis Rheum 2004; 51: 321–5
   PubMed Web of Science ®Google Scholar
• McCarty D. J. Gout without hyperuricemia. J Am Med Assoc 1994; 271: 302–3
   PubMed Web of Science ®Google Scholar
• Fam A. G. Difficult gout and new approaches for control of hyperuricemia in the allopurinol‐allergic patient. Curr Rheumatol Rep 2001; 3: 29–35
   PubMedGoogle Scholar
• Wortmann R. L., Kelley W. N. Kelley's textbook of rheumatology, 7th edn, E. D Jr Harris. WB Saunders Company, Philadelphia 2005; 1402–29
   Google Scholar
• Wortmann R. L. Harrison's principals of internal medicine, 16th edn, E Braunwald, A. S Fauci, D. L Kasper, S. L Hauser, D. L Longo, J. L Jameson. McGraw‐Hill, New York 2005; 2308–13
   Google Scholar
• Palella T. D., Kelley W. N. An approach to hyperuricemia and gout. Geriatrics 1984; 39: 89–102
   PubMed Web of Science ®Google Scholar
• Baer A. N. Principles of medical biology, vol. 8C. Molecular and cellular pharmacology, E. E Bittar, N Bittar. JAI Press Inc., Greenwich, CT 1997; 723–35
   Google Scholar
• Simkin P. A. Management of gout. Ann Intern Med 1979; 90: 812–16
   PubMed Web of Science ®Google Scholar
• Fam A. G. Should patients with interval gout be treated with urate lowering drugs?. J Rheumatol 1995; 22: 1621–3
   PubMed Web of Science ®Google Scholar
• Becker M. A., Schumacher H. R Jr., Wortmann R. L., MacDonald P. A., Palo W. A., Eustace D., et al. Febuxostat, a novel nonpurine selective inhibitor of xanthine oxidase. Arthritis Rheum 2005; 52: 916–23
   PubMed Web of Science ®Google Scholar
• Kunck R. W., Duncan G., Watson D., Kuncl R. W., Duncan G., Watson D., Alderson K., Rogawski M. A., Peper M. Colchicine myopathy and neuropathy. N Engl J Med 1987; 316: 1562–5
   PubMed Web of Science ®Google Scholar
• Fam A. G. Gout in the elderly: clinical presentation and treatment. Drugs Aging 1998; 13: 229–43
   PubMed Web of Science ®Google Scholar
• Kot T. V., Day R. D., Brooks P. M. Preventing acute gout when starting allopurinol therapy. Colchicine or NSAIDs?. Med J Aust 1993; 159: 182–4
   PubMed Web of Science ®Google Scholar
• Schumacher H. R., Smolyo A. P., Tse R. L., Maurer K. Arthritis associated with apatite crystals. Ann Intern Med 1977; 87: 411–16
   PubMed Web of Science ®Google Scholar
• Schumacher H. R. Crystal‐induced arthritis: an overview. Am J Med 1996; 100: 46S–52S
   PubMed Web of Science ®Google Scholar
• Wallace S. L., Singer J. Z. Therapy in gout. Rheum Dis Clin North Am 1988; 14: 441–57
   PubMed Web of Science ®Google Scholar
• Perez‐Ruiz F., Calabozo M., Herrero‐Beites A. M., Garcia‐Erauskin G., Pijoan J. I. Improvement in renal function in patients with chronic gout after proper control of hyperuricemia and gouty bouts. Nephron 2000; 86: 287–91
   PubMed Web of Science ®Google Scholar
• Choi H. K., Mount D. B., Reginato A. M., American College of Physicians American Physiological Society. Pathogenesis of gout. Ann Intern Med 2005; 143: 499–516
   PubMed Web of Science ®Google Scholar
• Stamp L., Gow P., Sharples K., Raill B. The optional use of allopurinol: an audit of allopurinol use in South Auckland. Aust N Z J Med 2000; 30: 567–72
   PubMedGoogle Scholar
• Harris M., Bryant L. R., Danaher P., Alloway J. A. Effect of low dose daily aspirin on serum urate levels and urinary excretion in patients receiving probenecid for gouty arthritis. J Rheumatol 2000; 27: 2873–6
   PubMed Web of Science ®Google Scholar
• Perez‐Ruiz F., Gomez‐Ullate P., Amenabar J. J., Zarraga S., Calabozo M., Herrero‐Beites A. M., et al. Long‐term efficacy of hyperuricemia treatment in renal transplant patients. Nephrol Dialysis Transplant 2003; 18: 603–6
   PubMed Web of Science ®Google Scholar
• Bieber J. D., Terkeltaub R. A. Gout: on the brink of novel therapeutic options for an ancient disease. Arthritis Rheum 2004; 50: 2400–14
   PubMed Web of Science ®Google Scholar
• Perez‐Ruiz F., Hernando I., Perez‐Ruiz F., Hernando I., Villar I., Nolla J. M. Correction of allopurinol dosing should be based on clearance of creatinine, but not plasma creatinine levels: another insight to allopurinol‐related toxicity. J Clin Rheumatol 2005; 11: 129–33
   PubMed Web of Science ®Google Scholar
• Perez‐Ruiz F., Alonso‐Ruiz A., Calabozo M., Herrero‐Beites A., Garcia‐Erauskin G., Ruiz‐Lucea E. Efficacy of allopurinol and benzbromarone for the control of hyperuricaemia. A pathogenic approach to the treatment of primary chronic gout. Ann Rheum Dis 1998; 57: 545–9
   PubMed Web of Science ®Google Scholar
• Becker M. A., Schumacher HR J. r., Wortmann R. L., et al. Febuxostat versus allopurinol in patients with hyperuricemia and gout. N Engl J Med 2005; 353: 2450–61
   PubMed Web of Science ®Google Scholar
• Schumacher H. R., Becker M. A., Wortmann R. L., MacDonald P. A., Hunt B., Streit J., Ladermacher C., Joseph‐Ridge N. Febuxostat versus allopurinol and placebo in subjects with hyperuricemia and gout. Arthritis Rheum 2005; 52((Suppl))S680
   Google Scholar
• Singer J. Z., Wallace S. L. The allopurinol hypersensitivity syndrome: unnecessary morbidity and mortality. Arthritis Rheum 1986; 29: 82–7
   PubMed Web of Science ®Google Scholar
• Weiner J. M., Mudge G. H. A. G Gillman, T. W Rall, A. W Nies, P Taylor. Pergamon Press, New York 1990; 920
   Google Scholar
• Hande K. R., Noone R. M., Stone W. I. Severe allopurinol toxicity: description and guidelines for presentation in patients with renal insufficiency. Am J Med 1984; 76: 47–53
   PubMed Web of Science ®Google Scholar
• Becker M. A., Schumacher H. R Jr., Wortmann R. L., MacDonald P., Palo W. A., Joseph‐Ridge N. Febuxostat, a novel nonpurine selective inhibitor of xanthine oxidase therapy in allopurinol intolerant patients. Arthritis Rheum 2004; 50((Suppl))S336
   PubMed Web of Science ®Google Scholar
• Wortmann R. L. Recent advances in the management of gout and hyperuricemia. Curr Opin Rheumatol 2005; 17: 319–24
   PubMed Web of Science ®Google Scholar
• US National Institutes of Health. Pegylated Recombinant Mammalian Uricase (PEG‐Uricase) as Treatment for Refractory Gout., Phase II Trial. ClinicalTrials.gov; Identifier NCT00111657
   Google Scholar
• Perez‐Ruiz F., Alonso‐Ruiz A., Calabozo M., Duruelo J. Treatment of gout after transplantation. Br J Rheumatol 1998; 37: 580–6
   PubMedGoogle Scholar
• Jacobs F., Mamzer‐Bruneel M. F., Skhiri H., Thervet E., Legendre C., Kreis H. Safety of the mycophenolate mofetil–allopurinol combination in kidney transplant recipients with gout. Transplantation 1997; 64: 1087–91
   PubMed Web of Science ®Google Scholar
• Choi H. K., Atkinson K., Karlson E. W., Willett W., Curhan G. Alcohol intake and risk of incident gout in men. A prospective study. Lancet 2004; 363: 1277–81
   PubMed Web of Science ®Google Scholar
• Ghany M., Hoofnagle J. H. Harrison's principals of internal medicine, 16th edn, E Braunwald, A. S Fauci, D. L Kasper, S. L Hauser, D. L Longo, J. L Jameson. McGraw‐Hill, New York 2005; 1808–13
   Google Scholar
• Maesaka J. K., Fishbane S. Regulation of renal urate excretion: a critical review. Am J Kidney Dis 1998; 32: 917–25
   PubMed Web of Science ®Google Scholar
• Dessein P. H., Shipton E. A., Stanwix A. E., Joffe B. I., Ramokgadi J. Beneficial effects of weight loss associated with moderate calorie/carbohydrate restriction, and increased proportional intake of protein and unsaturated fat on serum urate and lipoprotein levels in gout: a pilot study. Ann Rheum Dis 2000; 59: 539–48
   PubMed Web of Science ®Google Scholar
• Choi H. K., Liu S. Intake of purine‐rich foods, protein, and dairy products and relationship to serum levels of uric acid: the Third National Health and Nutrition Examination Survey. Arthritis Rheum 2005; 52: 283–9
   PubMed Web of Science ®Google Scholar
• Fam A. G. Gout, diet and the insulin resistance syndrome. J Rheumatol 2002; 29: 1350–6
   PubMed Web of Science ®Google Scholar
• Yamamoto T., Moriwaki Y., Takahashi S., Tsutsumi Z., Hada T. Effect of fenofibrate on plasma concentration and urinary excretion of purine bases and oxypurinol. J Rheumatol 2001; 28: 2294–7
   PubMed Web of Science ®Google Scholar
• Minghelli G., Seydoux C., Goy J. J., Burnier M. Uricosuric effect of the angiotensin II receptor antagonist losartan in heart transplant recipients. Transplantation 1998; 66: 268–71
   PubMed Web of Science ®Google Scholar
• Wurzner G., Gerster J. C., Chiolero A., Maillard M., Fallab‐Stubi C. L., Brunner H. R., et al. Comparative effects of losartan and irbesartan on serum uric acid in hypertensive patients with hyperuricaemia and gout. J Hypertens 2001; 19: 1855–60
   PubMed Web of Science ®Google Scholar
• Townshend D., Vasu P. Gouty tenosynovitis – more common than we think?. N Z Med J 2004; 117: U749
   PubMedGoogle Scholar
• Wortmann R. L. The treatment of gout: the use of an analogy. Am J Med 1998; 105: 513–16
   PubMed Web of Science ®Google Scholar
• Niskanen L. K., Laaksonen D. E., Nyyssonen K., Alfthan G., Lakka H. M., Lakka T. A., et al. Uric acid level as a risk factor for cardiovascular and all‐cause mortality in middle‐aged men. Arch Intern Med 2004; 164: 1546–51
   PubMed Web of Science ®Google Scholar